Hemab Therapeutics Holdings, Inc. Common Stock(COAG)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
- Exchange
- XNAS
- Market Cap
- $1.9B
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic thera…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | — | 0 |
| Feb | — | 0 |
| Mar | — | 0 |
| Apr | — | 0 |
| May | +5.56% | 1 |
| Jun | +30.94% | 1 |
| Jul | +31.46% | 1 |
| Aug | -4.17% | 1 |
| Sep | -17.11% | 1 |
| Oct | — | 0 |
| Nov | — | 0 |
| Dec | — | 0 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: COAG
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Technical indicators suggest a neutral market with no clear direction.
- Recent news headlines have been positive, but the company's beta is high, indicating increased volatility.
- Risk management considerations are crucial due to the stock's sensitivity to market movements.
Investment Thesis: COAG's recent clinical data and product developments in von Willebrand disease and heavy menstrual bleeding may drive future growth. However, the high-beta profile and volatility indicate a higher risk profile.
Recent News Sentiment Impact: The positive sentiment from recent headlines (Hemab Therapeutics' presentations at ISTH 2026 Congress and closing of upsized initial public offering) has contributed to the stock's moderate price movement.
Technical Analysis
Trend Direction:
- Short-term: NEUTRAL
- Medium-term: NEUTRAL
- Long-term: BEARISH (based on SMA 200 not available)
Support/Resistance Levels: $44.95 (lower Bollinger Band), $50.24 (SMA 20 and EMA 12)
Momentum Signals:
- RSI interpretation: NEUTRAL (52.35)
- MACD signal: BULLISH (crossed above the signal line)
- Bollinger Bands position: NEUTRAL (price near middle band)
Volume Analysis: Volume trends are mixed, but institutional interest is moderate with an OBV of 9791974.76.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines from Hemab Therapeutics' presentations and initial public offering closing have contributed to the stock's price movement.
Sentiment Assessment: POSITIVE (aggregate sentiment)
Catalyst Identification: Upcoming earnings announcements and product developments in von Willebrand disease and heavy menstrual bleeding may drive future growth.
Market Narrative: The positive news headlines align with the technical signals, suggesting a moderate risk profile.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock (beta: 1.43 vs SPY)
Volatility Regime: Current volatility is higher than historical levels (HV20 62.7%, HV30 72.9%, HV60 88.9%)
Options Market Signals: No options data available.
Downside Protection: Support levels are at $44.95, and risk management considerations are crucial due to the high-beta profile.
Market Context & Positioning
Sector Performance: COAG is a biotech stock, which has been performing relatively well compared to other sectors.
Institutional Activity: Moderate institutional interest with an OBV of 9791974.76.
Correlation Analysis: The stock moves moderately correlated (R-squared: 0.19) with the broader market.
Relative Valuation: COAG is positioned within a trading range, but its beta and volatility suggest a higher risk profile.
Key Levels & Action Items
Critical Price Levels: $44.95 (lower Bollinger Band), $50.24 (SMA 20 and EMA 12)
Breakout/Breakdown Levels: No specific levels available due to the neutral market trend.
Time-Sensitive Catalysts: Upcoming earnings announcements and product developments in von Willebrand disease and heavy menstrual bleeding.
Risk Management: Stop-loss levels should be set near $44.95, and position sizing considerations are crucial due to the high-beta profile.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 1.22
- Correlation (SPY)
- 16.8%
- R²
- 0.03
- Ann. Volatility
- 92.1%
- SPY Volatility
- 12.7%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Peter Kolchinsky | 10%+ Owner | Buy (P) | +270,676 | $24.97 | $6.76M | EDGAR |
| 2026-05-21 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | Buy (P) | +19,192 | $24.96 | $479.1K | EDGAR |
| 2026-05-14 | Rajeev M. Shah | 10%+ Owner | Buy (P) | +25,548 | $24.90 | $636.1K | EDGAR |
| 2026-05-11 | RA Capital Healthcare Fund LP | 10%+ Owner | Buy (P) | +205,032 | $24.75 | $5.07M | EDGAR |
| 2026-05-06 | Novo Holdings A/S | 10%+ Owner | Conv (C) | +4,180,550 | — | EDGAR | |
| 2026-05-06 | Rajeev M. Shah | Director | Mixed | +46,071,090 | $18.39 | $313.34M | EDGAR |
| 2026-05-04 | Mads Nikolaj Behrndt-Eriksen | See Remarks | Grant (A) | +244,222 RSU | — | EDGAR | |
| 2026-05-04 | JOHN MARAGANORE | Director | Conv (C) | +35,948 | — | EDGAR | |
| 2026-05-04 | Catherine Madigan | Chief Medical Officer | Grant (A) | +194,150 opt | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 10%+ Owner | 6,383,114 | $242.37M | $6.76M | 1 | 2026-06-17 |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | 6,375,972 | $242.10M | $479.1K | 1 | 2026-05-21 |
| 3 | Rajeev M. Shah | Director | 6,372,170 | $241.95M | $313.97M | 2 | 2026-05-14 |
| 4 | RA Capital Healthcare Fund LP | 10%+ Owner | 6,325,914 | $240.19M | $5.07M | 1 | 2026-05-11 |
| 5 | Novo Holdings A/S | 10%+ Owner | 4,180,550 | $158.74M | $0 | 1 | 2026-05-06 |
| 6 | JOHN MARAGANORE | Director | 35,948 | $1.36M | $0 | 1 | 2026-05-04 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.